TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways
Akihiro Miura, Hiroshi Sootome, Naoya Fujita, Takamasa Suzuki, Hiroto Fukushima, Shinji Mizuarai, Norio Masuko, Kimihiro Ito, Akihiro Hashimoto, Yoshihiro Uto, T Sugimoto, Hidekazu Takahashi, Morihiro Mitsuya, Hiroshi Hirai
Topics & Concepts
Trk receptorCancer researchKinaseBiologyIn vivoAurora kinaseTropomyosin receptor kinase AMitosisMolecular biologyCell biologyCellReceptorCell cycleBiochemistryNeurotrophinGeneticsMicrotubule and mitosis dynamicsProtein Degradation and InhibitorsCancer-related Molecular Pathways